Curcuma longa Extract Exerts a Myorelaxant Effect on the Ileum and Colon in a Mouse Experimental Colitis Model, Independent of the Anti-Inflammatory Effect

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Aldini, Rita ^a   Budriesi, Roberta ^b   Roda, Giulia ^a,c   Micucci, Matteo ^b   Ioan, Pierfranco ^b   D'Errico Grigioni, Antonia ^a   Sartini, Alessandro ^a   Guidetti, Elena ^a   Marocchi, Margherita ^a   Cevenini, Monica ^a   Rosini, Francesca ^a   Montagnani, Marco ^a   Chiarini, Alberto ^b   Mazzella, Giuseppe ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c MOUNT SINAI HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE; CARBACHOL; CURCUMA LONGA EXTRACT; DEXTRAN SULFATE; PLACEBO;

ACUTE COLITIS; ACUTE DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC COLITIS; CHRONIC DISEASE; COLITIS; COLON MOTILITY; CONTROLLED STUDY; DISEASE MODEL; ILEUM CONTRACTION; ILEUM MOTILITY; MOUSE; MUSCLE RELAXATION; NONHUMAN; TREATMENT DURATION;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTI-INFLAMMATORY AGENTS; ATROPINE; CARBACHOL; CARDIOTONIC AGENTS; COLITIS; COLON; CURCUMA; ILEUM; INFLAMMATION; INTESTINES; MALE; MICE; MICE, INBRED BALB C; MUSCLE RELAXANTS, CENTRAL; PLANT EXTRACTS;

CURCUMA; CURCUMA LONGA; MUS;

EID: 84866314266     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044650     Document Type: Article

References (63)

1. Strober W, Fuss I, Mannon P, (2007) The fundamental basis of inflammatory bowel disease. J Clin Invest 117: 514-521.
2. Xavier RJ, Podolsky DK, (2007) Unravelling the pathogenesis of inflammatory bowel disease. Nature 448: 427-34.
3. Triantafillidis JK, Merikas E, Georgopoulos F, (2011) Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther 5: 185-210.
4. Jacobson K, McHugh K, Collins SM, (1995) Experimental colitis alters myenteric nerve function at inflamed and non-inflamed sites in the rat. Gastroenterology 109: 718-22.
5. Aube AC, Cherbut C, Barbier M, Xing JH, Roze C, et al. (1999) Altered myoelectrical activity in non-inflamed ileum of rats with colitis induced by trinitrobenzenesulphonic acid. Neurogastroenterol Motil 11: 55-62.
6. Blandizzi C, Fornai M, Colucci R, Antonioli L, Bernardini N, et al. (2003) Altered prejunctional modulation of intestinal cholinergic and noradrenergic pathways by alpha2-adrenoceptors in the presence of experimental colitis. Br J Pharmacol 139: 309-20.
7. Kohno N, Nomura M, Okamoto H, Kaji M, Ito S, (2006) The use of electrogastrography and external ultrasonography to evaluate gastric motility in Crohn's disease. J Med Invest 53(3-4): 277-84.
8. Vrees MD, Pricolo VE, Potenti FM, Cao W (2002) Abnormal motility in patients with ulcerative colitis: the role of inflammatory cytokines. Arch Surg 137: 439-445; discussion 445-436.
9. Tomita R, Munakata K, Tanjoh K, (1998) Role of non-adrenergic non-cholinergic inhibitory nerves in the colon of patients with ulcerative colitis. J Gastroenterol 33: 48-52.
10. Vasina V, Barbara G, Talamonti L, Stanghellini V, Tonini M, et al. (2006) Enteric neuroplasticity evoked by inflammation. Auton Neurosci 126-127: 264-72.
11. Qureshi S, Song J, Lee HT, Koh SD, Hennig GW, Perrino BA (2010) CaM kinase II in colonic smooth muscle contributes to dysmotility in murine DSS-colitis. Neurogastroenterol Motil 22: 186-186-95, e64.
12. Motagally MA, Neshat S, Lomax AE, (2009) Inhibition of sympathetic N-type voltage-gated Ca2+ current underlies the reduction in norepinephrine release during colitis. Am J Physiol Gastrointest Liver Physiol 296: G1077-84.
13. Sato K, Ninomiya H, Ohkura S, Ozaki H, Nasu T, (2006) Impairment of PAR-2-mediated relaxation system in colonic smooth muscle after intestinal inflammation. Br J Pharmacol1 48: 200-7.
14. Mizuta Y, Isomoto H, Takahashi T, (2000) Impaired nitrergic innervation in rat colitis induced by dextran sulfate sodium. Gastroenterology 118: 714-23.
15. Mattar MC, Lough D, Pishvaian MJ, Charabaty A, (2011) Current management of inflammatory bowel disease and colorectal cancer. Gastrointest Cancer Res 4: 53-61.
16. Lim AW, Panaccione R, Seow CH, (2011) Exploring the role of monitoring anti-TNFα drug and antibody levels in the management of inflammatory bowel disease. Therap Adv Gastroenterol 4: 145-51.
17. Papadakis KA, Targan SR, (2000) The role of chemokines and chemokine receptors in mucosal inflammation. Inflamm Bowel Dis 6: 303-13.
18. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, et al. (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 335: 2462-76.
19. Ammon HP, Wahl MA, (1991) Pharmacology of Curcuma longa. Planta Med 57: 1-7.
20. Singh AK, Sidhu GS, Deepa T, Maheshwari RK, (1996) Curcumin inhibits the proliferation and cell cycle progression of human umbilical vein endothelial cell. Cancer Lett 107: 109-15.
21. Negi PS, Jayaprakasha GK, Jagan Mohan Rao L, Sakariah KK, (1999) Antibacterial activity of turmeric oil: a byproduct from curcumin manufacture. J Agric Food Chem 47: 4297-4300.
22. Jain SK, (1994) Ethnobotany and research on medicinal plants in India. Ciba Found Symp 185: 153-64.
23. Huang TS, Lee SC, Lin JK, (1991) Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells. Proc Natl Acad Sci USA 88: 5292-5296.
24. Xu YX, Pindolia KR, Janakiraman N, (1997) Curcumin, a compound with anti-inflammatory and anti-oxidant properties, down-regulates chemokine expression in bone marrow stromal cells. Exp Hematol 25: 413-422.
25. Ahmed T, Gilani AH, (2008) Inhibitory effect of curcuminoids on acetylcholinesterase activity and attenuation of scopolamine-induced amnesia may explain medicinal use of turmeric in Alzheimer's disease. Pharmacol Biochem Behav 91: 554-9.
26. Singh G, Kapoor IP, Singh P, de Heluani CS, de Lampasona MP, et al. (2010) Comparative study of chemical composition and antioxidant activity of fresh and dry rhizomes of turmeric (Curcuma longa Linn.).Food Chem Toxicol. 48: 1026-31.
27. Camacho-Barquero L, Villegas I, Sánchez-Calvo JM, Talero E, Sanches-Fidalgo S, et al. (2007) Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis. Int Immunopharmacol 3: 333-42.
28. Sugimoto K, Hanai H, Tozawa K, Aoshi T, Uchijima M, et al. (2002) Curcumin prevents and ameliorates trinitrobenzenesulfonic acid-induced colitis in mice. Gastroenterology 123: 1912-22.
29. Claramunt RM, Bouissane L, Cabildo MP, Cornago MP, Elguero J, et al. (2009) Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloproteinases. Bioorg Med Chem 171: 290-6.
30. Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, et al. (2006) Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial,. Clin Gastroenterol Hepatol 12: 1502-6.
31. Jian YT, Mai GF, Wang JD, Zhang YL, Luo RC, Fang YX, (2005) Preventive and therapeutic effects of NF-kappaB inhibitor curcumin in rats colitis induced by trinitrobenzene sulfonic acid. World J Gastroenterol 11: 1747-52.
32. Salh B, Assi K, Templeman V, Parhar K, Owen D, et al. (2003) Curcumin attenuates DNB-induced murine colitis. Am J Physiol, Gastrointest Liver Physiol 285: G235-43.
33. Ukil A, Maity S, Karmakar S, Datta N, Vedasiromoni JR, et al. (2003) Curcumin, the major component of food flavorturmeric, reduces mucosal injury in trinitrobenzenesulphonic acid induced colitis. Br J Pharmacol 139: 209-18.
34. Bharti AC, Donato N, Singh S, Aggarwal BB, (2003) Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 101: 1053-62.
35. Han SS, Keum YS, Seo HJ, Surh YJ, (2002) Curcumin suppresses activation of NF-kappaB and AP-1 induced by phorbol ester in cultured human promyelocytic leukemia cells. J Biochem Mol Biol 35: 337-42.
36. Singh S, Aggarwal BB, (1995) Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane)[corrected]. J Biol Chem 270: 24995-25000.
37. Xu YX, Pindolia KR, Janakiraman N, Chapman RA, Gautam SC, (1977) Curcumin inhibits IL1 alpha and TNF-alpha induction ofAP-1 and NF-kB DNA-binding activity in bone marrow stromal cells. Hematopathol Mol Hematol 11: 49-62.
38. Deguchi Y, Andoh A, Inatomi O, Yagi I, Bamaba S, et al. (2007) Curcumin prevents the development of Dextran Sulfate Sodium (DSS)-induced experimental colitis. Dig Dis Sci 52: 2993-8.
39. Kim GY, Kim KH, Lee SH, Yoon MS, Lee HJ, et al. (2005) Curcumin inhibits immunostimulatory function of dendritic cells: MAPKs and translocation of NF-kappa B as potential targets. J Immunol 174: 8116-24.
40. Shimouchi A, Nose K, Takaoka M, Hayashi H, Kondo T, (2009) Effect of dietary turmericon breath hydrogen. Dig Dis Sci 54: 1725-9.
41. Kumar A, Purwar B, Shrivastava A, Pandey S, (2010) Effects of curcumin on the intestinal motility of albino rats. Indian J Physiol Pharmacol 54: 284-8.
42. Itthipanichpong C, Ruangrungsi N, Kemsri W, Sawasdipanich A, (2006) Antispasmodic effects of curcuminoids on isolated guinea-pig ileum and rat uterus. J Med Assoc Thai 86Suppl 2: S2999-309.
43. Wirtz S, Neufert C, Weigmann B, Neurath MF, (2007) Chemically induced mouse models of intestinal inflammation. Nat Protoc 2: 541-6.
44. Fitzpatrick LR, Wang J, Le M, (2000) In vitro and in vivo effects of gliotoxin, a fungal metabolite: Efficacy against dextran sodium sulfate-induced colitis in rats. Dig Dis Sci 45: 2327-36.
45. Reagan-Shaw S, Nihal M, Ahmad N, (2008) Dose translation from animal to human studies revisited. FASEB J 22: 659-61.
46. Takemasa K, (1957) On the inorganic salts in the artificial nourishing fluid for isolated intestine. J Physiol Soc Japan 19: 1217-27.
47. Motulsky H, Christopoulos A (2003) Fitting Models to Biological Data Using Linear and Non Linear Regression, GrafhPad, La Jolla, CA, 2003. Available: www.graphpad.com/manual/Prism4/RegressionBook.pdf. Accessed 2010 May 10.
48. Arunlakshana D, Schild HO, (1959) Some Quantitative Uses of Drug Antagonists. Br J Pharmacol 14: 48-58.
49. Tallarida RJ, Murray RB (1987) Manual of Pharmacologic Calculations with Computer Programs, 2nd ed.; Springer-Verlag: New York.
50. Version 3.0; GraphPad Software, Inc., San Diego, CA, USA.
51. Larmonier CB, Midura-Kiela MT, Ramalingam R, Laubitz D, Janikashvili N, et al. (2011) Modulation of neutrophil motility by curcumin: implications for inflammatory bowel disease. Inflamm Bowel Dis 17 (2): 503-15.
52. Furness JB, (2008) The enteric nervous system: normal functions and enteric neuropathies. Neurogastroenterol Motil 20(Suppl 1): 32-8.
53. Grundy D, Schemann M, (2005) Enteric nervous system. Curr Opin Gastroenterol 21: 176-8.
54. Linden DR, (2003) Colitis: it is not just for the colon anymore. Br J Pharmacol 139: 185-6.
55. Linden DR, Sharkey KA, Ho W, Mawe GM, (2004) Cyclooxygenase-2 contributes to dysmotility and enhanced excitability of myenteric AH neurones in the inflamed guinea pig distal colon. J Physiol 557: 191-205.
56. Lomax AE, Fernandez E, Sharkey KA, (2005) Plasticity o f the entericnervous system during intestinal inflammation. Neurogastroenterol Motil 17: 4-15.
57. Akiho H, Ihara E, Motomura Y, Nakamura K, (2011) Cytokine-induced alterations of gastrointestinal motility in gastrointestinal disorders. World J Gastrointest Pathophysiol 15 2(5): 72-81.
58. Reddy SN, Bazzocchi G, Chan S, Akashi K, Villanueva-Meyer J, et al. (1991) Colonic motility and transit in health and ulcerative colitis. Gastroenterology 101: 1289-97.
59. Kinoshita K, Sato K, Hori M, Ozaki H, Karaki H, (2003) Decrease in activity of smooth muscle L-type Ca2+ channels and its reversal by NF-kappaB inhibitors in Crohn's colitis model. Am J Physiol- Gastrointestinal and Liver Physiology 285: G483-G493.
60. Myers BS, Martin JS, Dempsey DT, Parkman HP, Thomas RM, et al. (1997) Acute experimental colitis decreases colonic circular smooth muscle contractility in rats. Am J Physiol- Gastrointestinal and Liver Physiology 273: G928-G936.
61. Pazdrak K, Shi XZ, Sarna SK, (2004) TNFα suppresses human colonic circular smooth muscle cell contractility by SP1- and NF-κB-mediated induction of ICAM1.Gastroenterology. 127: 1096-109.
62. Ihara E, Beck PL, Chappellaz M, Wong J, Medlicott SA, et al. (2009) Mitogen-activated protein kinase pathways contribute to hypercontractility and increased Ca2+ sensitization in murine experimental colitis. Mol Pharmacol 75(5): 1031-41.
63. Kondo T, Nakajima M, Teraoka H, Unno T, Komori S, et al. (2011) Muscarinic receptor subtypes involved in regulation of colonic motility in mice: functional studies using muscarinic receptor-deficient mice. Eur J Pharmacol 670: 236-43.